Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 in progressing fibrosing interstitial lung disease
ACTRN12619001643167Phase 2Recruiting
- Sponsor
- Accendatech
- Start
- Jul 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dimethylaminomicheliolide in progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Accendatech. Primary endpoints: Safety and tolerability of ACT001 in PF-ILD, Change in pulmonary function in PF-ILD participants and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
dimethylaminomicheliolide
03
Conditions
progressive pulmonary fibrosis (PPF)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on ACTRN12619001643167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001643167.